You are here

Article info

Article menu
Immunotherapy biomarkers
Original research
Plasma cell marker, immunoglobulin J polypeptide, predicts early disease-specific mortality in HPV+ HNSCC

Authors

  • Shanying Gui Department of Otolaryngology-Head and Neck Surgery, University Hospitals, Cleveland, Ohio, USAUniversity Hospitals Seidman Cancer Center, Cleveland, Ohio, USA PubMed articlesGoogle scholar articles
  • W Quinn O'Neill Department of Otolaryngology-Head and Neck Surgery, University Hospitals, Cleveland, Ohio, USAUniversity Hospitals Seidman Cancer Center, Cleveland, Ohio, USA PubMed articlesGoogle scholar articles
  • Theodoros N Teknos Department of Otolaryngology-Head and Neck Surgery, University Hospitals, Cleveland, Ohio, USAUniversity Hospitals Seidman Cancer Center, Cleveland, Ohio, USACase Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA PubMed articlesGoogle scholar articles
  • Quintin Pan Department of Otolaryngology-Head and Neck Surgery, University Hospitals, Cleveland, Ohio, USAUniversity Hospitals Seidman Cancer Center, Cleveland, Ohio, USACase Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Quintin Pan; quintin.pan{at}uhhospitals.org
View Full Text

Citation

Gui S, O'Neill WQ, Teknos TN, et al
Plasma cell marker, immunoglobulin J polypeptide, predicts early disease-specific mortality in HPV+ HNSCC
Journal for ImmunoTherapy of Cancer 2021;9:e001259. doi: 10.1136/jitc-2020-001259

Publication history

  • Accepted January 20, 2021
  • First published March 18, 2021.
Online issue publication 
February 10, 2022

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.